This content is from: Patents

Pharma fears corruption of ‘hugely successful’ Bayh-Dole Act

Counsel at Pfizer, Novartis and Wolf Greenfield, and one of the bill’s authors, are concerned that COVID could compel parties to misuse a 40-year-old act that stimulates US innovation

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial